Log in to save to my catalogue

Antiangiogenic Therapy for Diabetic Nephropathy

Antiangiogenic Therapy for Diabetic Nephropathy

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5556994

Antiangiogenic Therapy for Diabetic Nephropathy

About this item

Full title

Antiangiogenic Therapy for Diabetic Nephropathy

Publisher

Cairo, Egypt: Hindawi Publishing Corporation

Journal title

BioMed research international, 2017-01, Vol.2017 (2017), p.1-12

Language

English

Formats

Publication information

Publisher

Cairo, Egypt: Hindawi Publishing Corporation

More information

Scope and Contents

Contents

Angiogenesis has been shown to be a potential therapeutic target for early stages of diabetic nephropathy in a number of animal experiments. Vascular endothelial growth factor (VEGF) is the main mediator for abnormal angiogenesis in diabetic glomeruli. Although beneficial effects of anti-VEGF antibodies have previously been demonstrated in diabetic...

Alternative Titles

Full title

Antiangiogenic Therapy for Diabetic Nephropathy

Authors, Artists and Contributors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5556994

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5556994

Other Identifiers

ISSN

2314-6133

E-ISSN

2314-6141

DOI

10.1155/2017/5724069

How to access this item